Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents

被引:153
作者
Molander, Pauliina [1 ,2 ]
af Bjorkesten, Clas-Goran
Mustonen, Harri [4 ]
Haapamaki, Johanna
Vauhkonen, Matti [3 ]
Kolho, Kaija-Leena [5 ]
Farkkila, Martti [2 ]
Sipponen, Taina
机构
[1] Maria Helsinki City Hosp, Dept Med, Div Gastroenterol, FIN-00099 Helsinki, Finland
[2] Univ Helsinki, Helsinki, Finland
[3] Univ Helsinki, Cent Hosp, Dept Med, Div Gastroenterol,Jorvi Hosp, Helsinki, Finland
[4] Univ Helsinki, Cent Hosp, Dept Surg, Biomedicum Helsinki, Helsinki, Finland
[5] Univ Helsinki, Cent Hosp, Childrens Hosp, Helsinki, Finland
关键词
Crohn's disease; ulcerative colitis; fecal markers; long-term outcome; infliximab; adalimumab; ILEOCOLONIC CROHNS-DISEASE; MAINTENANCE THERAPY; CLINICAL REMISSION; ULCERATIVE-COLITIS; ENDOSCOPIC SCORE; ACTIVITY INDEX; INFLIXIMAB; LACTOFERRIN; RELAPSE; MULTICENTER;
D O I
10.1002/ibd.22863
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Fecal calprotectin (FC) concentration is a useful surrogate marker for mucosal healing (MH) during tumor necrosis factor alpha (TNFa)-blocking therapy for inflammatory bowel disease (IBD). Our aim was to evaluate whether a normal FC after induction therapy with TNFa antagonist predicts the outcome of IBD patients during maintenance therapy. Methods: Sixty IBD patients (34 Crohn's disease [CD], 26 ulcerative colitis [UC]), treated with TNFa antagonists, either infliximab (n = 42) or adalimumab (n = 18), and having a documented FC level at baseline and after induction therapy were included. Disease activity was evaluated by partial Mayo score without endoscopy or HarveyBradshaw index at baseline, after induction, and at 12 months during maintenance therapy. Results: After induction, FC was normalized (=100 mu g/g) in 31 patients (52%, median 42 mu g/g, range 097), whereas the level remained elevated in 29 patients (48%, median 424 mu g/g, range 1165859). At 12 months, 26/31 (84%, 18 CD, 8 UC) of the patients with normal FC after induction were in clinical remission, whereas only 11/29 (38%, 9 CD, 2 UC) of those with an elevated (=100 mu g/g) postinduction FC were in clinical remission, P < 0.0001. After induction therapy with TNFa antagonists, a cutoff concentration of 139 mu g/g for FC had a sensitivity of 72% and a specificity of 80% to predict a risk of clinically active disease after 1 year. Conclusions: A normal FC after induction therapy with TNFa antagonists predicts sustained clinical remission in the majority of patients on scheduled therapy with active luminal disease. (Inflamm Bowel Dis 2012;)
引用
收藏
页码:2011 / 2017
页数:7
相关论文
共 50 条
  • [21] Fecal Calprotectin in Pediatric Inflammatory Bowel Disease: A Systematic Review
    Kostakis, Ioannis D.
    Cholidou, Kyriaki G.
    Vaiopoulos, Aristeidis G.
    Vlachos, Ioannis S.
    Perrea, Despina
    Vaos, George
    DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (02) : 309 - 319
  • [22] Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels
    Anssi Hmlinen
    Taina Sipponen
    Kaija-Leena Kolho
    World Journal of Gastroenterology, 2011, 17 (47) : 5166 - 5171
  • [23] Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study
    Ma, Christopher
    Lumb, Rowan
    Walker, Emily V.
    Foshaug, Rae R.
    Dang, ThucNhi T.
    Verma, Sanam
    Huang, Vivian W.
    Kroeker, Karen I.
    Wong, Karen
    Dieleman, Levinus A.
    Fedorak, Richard N.
    Halloran, Brendan P.
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (09) : 1643 - 1649
  • [24] Fecal Calprotectin as a Screening Marker for Inflammatory Bowel Disease
    Sridhar, Mathrubootham
    Kesavelu, Dhanasekhar
    INDIAN PEDIATRICS, 2019, 56 (03) : 249 - 250
  • [25] Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease
    Bressler, Brian
    Panaccione, Remo
    Fedorak, Richard N.
    Seidman, Ernest G.
    CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 29 (07): : 369 - 372
  • [26] Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?
    Di Ruscio, Mirko
    Vernia, Filippo
    Ciccone, Antonio
    Frieri, Giuseppe
    Latella, Giovanni
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (01) : 78 - 92
  • [27] FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease
    Rosenfeld, Greg
    Greenup, Astrid-Jane
    Round, Andrew
    Takach, Oliver
    Halparin, Lawrence
    Saadeddin, Abid
    Ho, Jin Kee
    Lee, Terry
    Enns, Robert
    Bressler, Brian
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (36) : 8211 - 8218
  • [28] Impact of Fecal Calprotectin Measurement on Decision-making in Children with Inflammatory Bowel Disease
    El-Matary, Wael
    Abej, Esmail
    Deora, Vini
    Singh, Harminder
    Bernstein, Charles N.
    FRONTIERS IN PEDIATRICS, 2017, 5
  • [29] Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control
    van Rheenen, Patrick F.
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (11) : 2018 - 2025
  • [30] Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease
    Lee, Ji Min
    Kim, Yoon Jae
    Lee, Kang-Moon
    Yoon, Hyuk
    Lee, Bo-In
    Kim, Dae Bum
    Kang, Donghoon
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2018, 53 (10-11) : 1280 - 1285